Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.

The matrix metalloproteinase (MMP) family of enzymes is comprised of critically important extracellular matrix remodeling proteases whose activity has been implicated in a number of key normal and pathologic processes. The latter include tumor growth, progression, and metastasis as well as the dysregulated angiogenesis that is associated with these events. As a result, these proteases have come to represent important therapeutic and diagnostic targets for the treatment and detection of human cancers. In this review, we summarize the literature that establishes these enzymes as important clinical targets, discuss the complexity surrounding their choice as such, and chronicle the development strategies and outcomes of their clinical testing to date. The status of the MMP inhibitors currently in US Food and Drug Administration approved clinical trials is presented and reviewed. We also discuss the more recent and successful targeting of this enzyme family as diagnostic and prognostic predictors of human cancer, its status, and its stage. This analysis includes a wide variety of human cancers and a number of human sample types including tissue, plasma, serum, and urine.

[1]  C. Pilarsky,et al.  ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. , 2008, European urology.

[2]  G. Weskamp,et al.  Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands , 2004, The Journal of cell biology.

[3]  Cheng-Long Huang,et al.  Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. , 2007, Lung cancer.

[4]  R. Ball,et al.  Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues , 2005, British Journal of Cancer.

[5]  M. Klempner,et al.  Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis , 1998, Cancer.

[6]  Robert Powers,et al.  Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design , 2000 .

[7]  B. de Strooper,et al.  ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Ralph Weissleder,et al.  In vivo molecular target assessment of matrix metalloproteinase inhibition , 2001, Nature Medicine.

[9]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[10]  E. Bauer,et al.  Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells , 1992, Journal of cellular physiology.

[11]  K. Suzuki,et al.  Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. , 1995, Endocrinology.

[12]  G. Fuller,et al.  Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo , 2004, Clinical and Experimental Metastasis.

[13]  T. Shiomi,et al.  ADAM28 is overexpressed in human non‐small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis , 2006, International journal of cancer.

[14]  M. Bissell,et al.  Targeting TACE-dependent EGFR ligand shedding in breast cancer. , 2007, The Journal of clinical investigation.

[15]  S. Arii,et al.  Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance , 2001, Cancer.

[16]  J. Neoptolemos,et al.  Comprehensive Analysis of Matrix Metalloproteinase and Tissue Inhibitor Expression in Pancreatic Cancer , 2004, Clinical Cancer Research.

[17]  G. Kristiansen,et al.  ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis , 2006, Virchows Archiv.

[18]  B. Fingleton MMPs as therapeutic targets--still a viable option? , 2008, Seminars in cell & developmental biology.

[19]  Gillian Murphy,et al.  Structure and function of matrix metalloproteinases and TIMPs. , 2006, Cardiovascular research.

[20]  K. Suzuki,et al.  Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. , 1994, The Journal of biological chemistry.

[21]  Jinxiang Han,et al.  Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients , 2008, BMC Cancer.

[22]  K. Ochi,et al.  Matrix Metalloproteinase-2 in Pancreatic Juice for Diagnosis of Pancreatic Cancer , 2002, Pancreas.

[23]  J. Folkman,et al.  The generation of endostatin is mediated by elastase. , 1999, Cancer research.

[24]  W. Stetler-Stevenson Tissue Inhibitors of Metalloproteinases in Cell Signaling: Metalloproteinase-Independent Biological Activities , 2008, Science Signaling.

[25]  C. Butterfield,et al.  Structural and Functional Uncoupling of the Enzymatic and Angiogenic Inhibitory Activities of Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) , 2003, Journal of Biological Chemistry.

[26]  John M. Whitelock,et al.  The Degradation of Human Endothelial Cell-derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases (*) , 1996, The Journal of Biological Chemistry.

[27]  F. Bolster,et al.  ADAM-17 predicts adverse outcome in patients with breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  J. Folkman,et al.  Regulation of Angiostatin Production by Matrix Metalloproteinase-2 in a Model of Concomitant Resistance* , 1999, The Journal of Biological Chemistry.

[29]  I. Poola,et al.  Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis , 2005, Nature Medicine.

[30]  M. Swellam,et al.  Diagnostic value of urinary molecular markers in bladder cancer. , 2003, Anticancer research.

[31]  P. Novotny,et al.  Low-Molecular-Weight Heparin in Patients With Advanced Cancer: A Phase 3 Clinical Trial , 2006 .

[32]  J. Thiery Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[33]  S. Loening,et al.  Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. , 2001, Urology.

[34]  G. Batist,et al.  Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  D. Johnston,et al.  The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  A. Sparreboom,et al.  Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[37]  I. Fidler,et al.  Macrophage-Derived Metalloelastase Is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma , 1997, Cell.

[38]  Satoshi O. Suzuki,et al.  Clinical Significance of Heparin-Binding Epidermal Growth Factor–Like Growth Factor and A Disintegrin and Metalloprotease 17 Expression in Human Ovarian Cancer , 2005, Clinical Cancer Research.

[39]  B. Fingleton,et al.  Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. , 2000, The Journal of clinical investigation.

[40]  S. Chandler,et al.  Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein. , 1996, Biochemical and biophysical research communications.

[41]  D. Albertson,et al.  Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability , 2005, Nature.

[42]  U. Felbor,et al.  Generation and degradation of human endostatin proteins by various proteinases , 2000, FEBS letters.

[43]  T. Turpeenniemi‐Hujanen,et al.  Matrix Metalloproteinase 2 (MMP-2) Immunoreactive Protein is Associated with Poor Grade and Survival in Brain Neoplasms , 2004, Journal of Neuro-Oncology.

[44]  D. Christiani,et al.  Matrix Metalloproteinase-1 Promoter Polymorphism and Lung Cancer Risk , 2005, Cancer Epidemiology Biomarkers & Prevention.

[45]  J. Grandis,et al.  Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer , 2007, Clinical Cancer Research.

[46]  I. Pucci‐Minafra,et al.  Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera , 2004, British Journal of Cancer.

[47]  T. Cloughesy,et al.  Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  F. Meyer,et al.  Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. , 2008, Human pathology.

[49]  M A Moses,et al.  Increased incidence of matrix metalloproteinases in urine of cancer patients. , 1998, Cancer research.

[50]  C. Petraki,et al.  Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. , 2000, Anticancer research.

[51]  M. Barbacid,et al.  Identification of Insulin-like Growth Factor-binding Protein-1 as a Potential Physiological Substrate for Human Stromelysin-3* , 1997, The Journal of Biological Chemistry.

[52]  E. Lengyel,et al.  Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  M. Moses,et al.  Making the cut: protease-mediated regulation of angiogenesis. , 2006, Experimental cell research.

[54]  S. Eccles,et al.  Use of plasma MMP‐2 and MMP‐9 levels as a surrogate for tumour expression in colorectal cancer patients , 2003, International journal of cancer.

[55]  Liz Y. Han,et al.  The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer , 2006, Clinical Cancer Research.

[56]  Michael R. Kroeger,et al.  Structure–Function Analysis of the ADAM Family of Disintegrin-Like and Metalloproteinase-Containing Proteins (Review) , 1999, Journal of protein chemistry.

[57]  P. Ongusaha,et al.  HB-EGF Is a Potent Inducer of Tumor Growth and Angiogenesis , 2004, Cancer Research.

[58]  H. Birkedal‐Hansen Proteolytic remodeling of extracellular matrix. , 1995, Current opinion in cell biology.

[59]  Li Yan,et al.  The Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Plays a Role in Breast Tumor Growth and Is Present in the Urine of Breast Cancer Patients , 2005, Clinical Cancer Research.

[60]  M. Mareel,et al.  Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. , 2001, Journal of cell science.

[61]  S. Raza,et al.  Urinary Metalloproteinases: Noninvasive Biomarkers for Breast Cancer Risk Assessment , 2008, Cancer Epidemiology Biomarkers & Prevention.

[62]  G. Murphy The ADAMs: signalling scissors in the tumour microenvironment , 2008, Nature Reviews Cancer.

[63]  C. Nadal,et al.  Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients , 2007, International journal of cancer.

[64]  E. Lengyel,et al.  Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. , 2001, Gynecologic oncology.

[65]  M. Duffy,et al.  ADAM-17 Expression in Breast Cancer Correlates with Variables of Tumor Progression , 2007, Clinical Cancer Research.

[66]  R. Khokha,et al.  The Role of Tissue Inhibitors of Metalloproteinases in Tumorigenesis and Metastasis , 2008, Critical reviews in clinical laboratory sciences.

[67]  D. Zurakowski,et al.  ADAM 12 Cleaves Extracellular Matrix Proteins and Correlates with Cancer Status and Stage* , 2004, Journal of Biological Chemistry.

[68]  H. Nagase,et al.  Progress in matrix metalloproteinase research. , 2008, Molecular aspects of medicine.

[69]  L. Matrisian,et al.  Matrix-degrading metalloproteinases in tumor progression. , 1994, Princess Takamatsu symposia.

[70]  Florian Kronenberg,et al.  Matrix Metalloproteinase 1 (MMP1) Is Associated with Early-Onset Lung Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[71]  J. Winer,et al.  Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. , 1992, The Journal of biological chemistry.

[72]  A. Noël,et al.  Matrix metalloproteinases at cancer tumor-host interface. , 2008, Seminars in cell & developmental biology.

[73]  G. Morgia,et al.  Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer , 2005, Urological Research.

[74]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[75]  S. Apte A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. , 2004, The international journal of biochemistry & cell biology.

[76]  H. Oral,et al.  Matrix Metalloproteinase-9 (MMP-9) Elevated in Serum but not in Bronchial Lavage Fluid in Patients with Lung Cancer , 2006, Tumori.

[77]  L. Kotra,et al.  Potent and Selective Mechanism-Based Inhibition of Gelatinases , 2000 .

[78]  H. Miyake,et al.  Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. , 2010, Urologic oncology.

[79]  A. Krüger,et al.  Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. , 2005, Cancer research.

[80]  D. Gouma,et al.  Evaluation of Matrix Metalloproteinase 7 in Plasma and Pancreatic Juice as a Biomarker for Pancreatic Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[81]  Pieter Koolwijk,et al.  Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. , 2008, Cardiovascular research.

[82]  G. Sledge,et al.  A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer , 2004, Clinical Cancer Research.

[83]  Bonnie F. Sloane,et al.  Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. , 2006, Cancer research.

[84]  Xìao-chun Xu,et al.  Prognostic significance of MMP‐9 and TIMP‐1 serum and tissue expression in breast cancer , 2008, International journal of cancer.

[85]  J. Fridman,et al.  Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  A. Strongin,et al.  Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-αv integrin regulates cross-talk between αvβ3 and α2β1 integrinsin breast carcinoma cells , 2003 .

[87]  V. Kosma,et al.  Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. , 2007, Gynecologic oncology.

[88]  P. Wingfield,et al.  TIMP-2 Mediated Inhibition of Angiogenesis An MMP-Independent Mechanism , 2003, Cell.

[89]  S. Zucker,et al.  Measurement of Matrix Metalloproteinases in Serum of Patients with Melanoma: Snarled in Technical Pitfalls , 2005, Clinical Cancer Research.

[90]  E. Baker,et al.  The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. , 2003, European journal of cancer.

[91]  R. Pierce,et al.  Matrix metalloproteinases generate angiostatin: effects on neovascularization. , 1998, Journal of immunology.

[92]  M. Moses,et al.  Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. , 2006, EXS.

[93]  Alex Y Strongin,et al.  An Alternative Processing of Integrin αv Subunit in Tumor Cells by Membrane Type-1 Matrix Metalloproteinase* , 2002, The Journal of Biological Chemistry.

[94]  R. Grobholz,et al.  Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients , 2004, Virchows Archiv.

[95]  J. Keski‐Oja,et al.  Epilysin (MMP-28) induces TGF-β mediated epithelial to mesenchymal transition in lung carcinoma cells , 2006, Journal of Cell Science.

[96]  W. Bode,et al.  Structural Studies on MMPs andTIMPs Wolfram Bode and Klaus Maskos , 2001 .

[97]  William C. Parks,et al.  Matrix metalloproteinases as modulators of inflammation and innate immunity , 2004, Nature Reviews Immunology.

[98]  C. López-Otín,et al.  Loss of collagenase-2 confers increased skin tumor susceptibility to male mice , 2003, Nature Genetics.

[99]  L. Golub,et al.  Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. , 1991, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[100]  L. Kotra,et al.  X-ray Absorption Studies of Human Matrix Metalloproteinase-2 (MMP-2) Bound to a Highly Selective Mechanism-based Inhibitor , 2001, The Journal of Biological Chemistry.

[101]  J. Mohler,et al.  In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer , 1997, Clinical & Experimental Metastasis.

[102]  Jack P. Witty,et al.  Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. , 1995, Cancer research.

[103]  M. Klagsbrun,et al.  Matrix Metalloproteinase-3 Releases Active Heparin-binding EGF-like Growth Factor by Cleavage at a Specific Juxtamembrane Site* , 1997, The Journal of Biological Chemistry.

[104]  D. Edwards,et al.  The ADAM metalloproteinases , 2008, Molecular Aspects of Medicine.

[105]  J. Kos,et al.  Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[106]  D. Wagner,et al.  Plasma storage at −80 °C does not protect matrix metalloproteinase-9 from degradation , 2005 .

[107]  L. Matrisian,et al.  A Protective Role for Matrix Metalloproteinase-3 in Squamous Cell Carcinoma , 2004, Cancer Research.

[108]  D. Zurakowski,et al.  Urinary Biomarkers Predict Brain Tumor Presence and Response to Therapy , 2008, Clinical Cancer Research.

[109]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[110]  L. Liotta,et al.  Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas , 2004, Clinical & Experimental Metastasis.

[111]  G. Giannelli,et al.  Role of Cell Surface Metalloprotease Mt1-Mmp in Epithelial Cell Migration over Laminin-5 , 2000, The Journal of cell biology.

[112]  M A Moses,et al.  Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[113]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[114]  L. Matrisian,et al.  Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues: Clinical and Experimental Applications , 1999, Annals of the New York Academy of Sciences.

[115]  T. Ørntoft,et al.  Molecular Profiling of ADAM12 in Human Bladder Cancer , 2006, Clinical Cancer Research.

[116]  D. Trudel,et al.  The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis , 2006, Breast Cancer Research.

[117]  Jingsong Xu,et al.  Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo , 2001, The Journal of cell biology.

[118]  T. Wobbes,et al.  Plasma Gelatinase Activity Does Not Reflect Disease Activity after Operation for Colorectal Cancer , 2005, Oncology.

[119]  M. Gilbert,et al.  Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial , 2008, Cancer Chemotherapy and Pharmacology.

[120]  Susan M. Kilroy,et al.  Tumor-Specific Urinary Matrix Metalloproteinase Fingerprinting: Identification of High Molecular Weight Urinary Matrix Metalloproteinase Species , 2008, Clinical Cancer Research.

[121]  S. Loening,et al.  Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. , 1998, Clinical chemistry.

[122]  C. Pilarsky,et al.  ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma , 2004, British Journal of Cancer.

[123]  Debra L Barton,et al.  Evaluation of shark cartilage in patients with advanced cancer , 2005, Cancer.

[124]  M. Hidalgo,et al.  Development of matrix metalloproteinase inhibitors in cancer therapy. , 2001, Journal of the National Cancer Institute.

[125]  Nasreen S Jessani,et al.  Activity-based probes for the proteomic profiling of metalloproteases. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[126]  J. Bartsch,et al.  Therapeutic benefits from targeting of ADAM family members. , 2004, Biochemistry.

[127]  J. McKay,et al.  Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer , 2002, Journal of clinical pathology.

[128]  Edward R. Smith,et al.  A RECURRENT CRANIOPHARYNGIOMA ILLUSTRATES THE POTENTIAL USEFULNESS OF URINARY MATRIX METALLOPROTEINASES AS NONINVASIVE BIOMARKERS: CASE REPORT , 2007, Neurosurgery.

[129]  M. Langenskiöld,et al.  Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer , 2005, International Journal of Colorectal Disease.

[130]  R. Dickson,et al.  Roles of the matrix metalloproteinases in mammary gland development and cancer , 1998, Breast Cancer Research and Treatment.

[131]  Fei Zhang,et al.  Tumor-derived Matrix Metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer , 2008, BMC Cancer.

[132]  A. Ullrich,et al.  Distinct ADAM Metalloproteinases Regulate G Protein-coupled Receptor-induced Cell Proliferation and Survival* , 2004, Journal of Biological Chemistry.

[133]  R. Fleischmajer,et al.  Tetracyclines: nonantibiotic properties and their clinical implications. , 2006, Journal of the American Academy of Dermatology.

[134]  Y. Cho,et al.  Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer. , 2007, Human pathology.

[135]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[136]  Ximing J. Yang,et al.  Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma. , 2009, Gynecologic oncology.

[137]  G. Aust,et al.  Differential Expression and Activity Status of MMP-1, MMP-2 and MMP-9 in Tumor and Stromal Cells of Squamous Cell Carcinomas of the Lung , 2002, Tumor Biology.

[138]  W. Bode,et al.  1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. , 1997, European journal of biochemistry.

[139]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[140]  C. Jumper,et al.  Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. , 2004, Respiratory medicine.

[141]  Pierre Ducrot,et al.  Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[142]  E. Yordan,et al.  Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  E. Armanasco,et al.  Plasma MMP‐9 (92 kDa‐MMP) activity is useful in the follow‐up and in the assessment of prognosis in breast cancer patients , 2003, International journal of cancer.

[144]  F. Loechel,et al.  Activation of ADAM 12 protease by copper , 2001, FEBS letters.

[145]  Y. Collan,et al.  Prognostic significance of matrix metalloproteinases‐1, ‐2, ‐7 and ‐13 and tissue inhibitors of metalloproteinases‐1, ‐2, ‐3 and ‐4 in colorectal cancer , 2007, International journal of cancer.

[146]  B. Têtu,et al.  Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. , 2008, American journal of clinical pathology.

[147]  C. Blobel,et al.  ADAMs: key components in EGFR signalling and development , 2005, Nature Reviews Molecular Cell Biology.

[148]  A. Reiner,et al.  Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. , 1998, Microvascular research.

[149]  Z. Werb,et al.  Matrix Metalloproteinase Stromelysin-1 Triggers a Cascade of Molecular Alterations That Leads to Stable Epithelial-to-Mesenchymal Conversion and a Premalignant Phenotype in Mammary Epithelial Cells , 1997, The Journal of cell biology.

[150]  M. Ramsby,et al.  Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma. , 2003, Analytical biochemistry.